Navigation Links
AssureRx Adds VP of Sales and Marketing
Date:4/28/2008

Personalized medicine company prepares for commercial launch of first

product

CINCINNATI, April 28 /PRNewswire/ -- AssureRx, a personalized medicine company, announced that Al Lucas has joined the Company as vice president of sales and marketing. He will be responsible for developing the marketing plan and initial launch strategy, building the sales force, and leading the commercial introduction of the Company's first product. Lucas is an experienced pharmaceutical sales and marketing leader with more than 20 years of experience at companies such as Novartis, Pharmacia, and The Upjohn Company. In his various roles with those companies, he has participated in more than 15 successful product launches, including the highly successful Zyvox (linezolid). Additionally, he played roles in the planning, hiring and training of multiple sales forces.

"I was very excited about the opportunity to join AssureRx in this early stage," said Lucas. "The personalized medicine movement will change the way medicine is practiced, and AssureRx has positioned itself to become the market leader within the largest potential segment, the neuropsychiatric field. The Company has solid relationships with the thought leaders in psychopharmacogenetic research, which supports the development of our products. We will leverage this cutting-edge technology to bring tools to the marketplace which will help physicians provide individualized and highly-specific care to each patient," Lucas continued. "These are the hallmarks of personalized medicine."

Mark Byrne, AssureRx CEO added, "We are extremely pleased that Al has joined AssureRx. He brings a demonstrated track record of successful new product introductions and is experienced in the neuro-pscyh market segment. The addition of Al will accelerate our commercial introduction."

About AssureRx

AssureRx, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize the industry-leading personalized medicine technology of Cincinnati Children's Hospital and the Mayo Clinic. The proprietary technology is based on pharmacogenetics -- the study of the genetic factors that influence an individual's response to drug treatments -- as well as evidence-based medicine and clinical pharmacology. The result is a trusted guide that helps doctors select the right drug at the right dose right now.


'/>"/>
SOURCE AssureRx, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
2. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
6. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
7. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
8. Dilon Technologies Closes First Quarter With Record Sales
9. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):